Supra-additive effect of chronic inflammation and atherogenic dyslipidemia on developing type 2 diabetes among young adults: a prospective cohort study

• DOI: 10.1186/s12933-023-01878-5
• Publication Date: 2023-07-15T18:01:19Z
• Authors: Yulong Lan; Dan Wu; Zhiwei Cai; Yuancheng Xu; Xiong Ding; Weiqiang Wu; Shaocong Lan; Lan Chen; Zheng Guo; Lois Balmer; Xingang Li; Manshu Song; Shouling Wu; Jingli Gao; Wei Wang; Youren Chen
• Keywords: Dyslipidemia; Angiology

Both elevated inflammation and atherogenic dyslipidemia are prominent in young-onset diabetes increasingly identified as biologically intertwined processes that contribute to diabetogenesis. We aimed investigate the age-specific risks of type 2 (T2D) upon concomitant chronic dyslipidemia.Age-stratified Cox regression analysis risk incident co-exposure time-averaged cumulative high-sensitivity C-reactive protein (CumCRP) index plasma (CumAIP) among 42,925 nondiabetic participants from a real-world, prospective cohort (Kailuan Study).During median 6.41 years follow-up, 3987 T2D developed. Isolated CumAIP CumCRP were significantly associated with entire across all age subgroups. jointly an increased (P-interaction = 0.0126). Compared < -0.0699 1 mg/L, ≥ - 0.0699 3 mg/L had significant hazard ratio (HR) [2.55 (2.23-2.92)] after adjusting for socio-demographic, life-style factors, family history diabetes, blood pressure, renal function medication use. The co-exposure-associated varied greatly by distribution 0.0193): 40 years, 6.26 (3.47-11.28); 40-49 2.26 (1.77-2.89); 50-59 2.51 (2.00-3.16); 60-69 2.48 (1.86-3.30); 70 2.10 (1.29-3.40). In young adults (< 45 years), both exposures supra-additive effect on diabetogenesis (relative excess due interaction: 0.80, 95% CI 0.10-1.50).These findings highlight need combined assessment management primary prevention against T2D, particularly adults. clinical benefit derived dual-target intervention will exceed sum each part alone